British Journal of Clinical Pharmacology 1999: Vol 47 Table of Contents

7 Pages·1999·1.4 MB·English

The British Journal of
Clinical Pharmacology
Volume 47
1999
Published for
The British Pharmacological Society by
Blackwell Science
© 1999 Blackwell Science Ltd
Osney Mead, Oxford OX2 OEL
25 John Street, London WCIN 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia
Other Editorial Offices:
Blackwell Wissenschafts- Verlag GmbH
Kurfiirstendamm 57
1707 Berlin
Germany
Blackwell Science KK
MG Kodenmacho Building
7-10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan
Published on behalf of
The British Pharmacological Society
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or
by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the
copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific
clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC)
Transactional Reporting Service, provided that the base fee of $14.00 per copy is paid directly to CCC, 222 Rosewood Drive,
Suite 910, Danvers, MA 01923, USA. 0206-5251/98 $14.00/0. (For copying beyond that permitted by Sections 107 or 108 of the
US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for
advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to
the Editor.
Typeset and printed by The Charlesworth Group, Huddersfield
Contents
Volume 47, Number 1, January 1999
Anniversary commentaries Vascular pharmacodynamics
Green into silver: G. T. Tucker, D. Back & G. McInnes Ketotifen and cardiovascular effects of xamoterol
BJCP 25th Anniversary: C. George following single and chronic dosing in healthy volunteers:
Drug discovery and development in the molecular era: R. F. Schafers, I. Karl, K. Mennicke, A. E. Daul,
C. T. Dollery T. Philipp & O. E. Brodde
How will knowledge of the human genome affect drug Differential vascular %,-adrenoceptor antagonism by
therapy?: D. G. Grahame-Smith tamsulosin and terazosin: R. F. Schdfers, B. Fokuhl,
Clinical pharmacology and drug regulation: A. Wasmuth, H. Schumacher, K. Taguchi, C. de Mey,
A. M. Breckenridge T. Philipp & M. C. Michel
Vasconstriction in human isolated middle meningeal
arteries: determining the contribution of 5-HT,,- and
Reviews 5-HT,-receptor activation: Z. Razzaque, M. A. Heald,
The use of atypical antipsychotics in the management of J. D. Pickard, L. Maskell, M. S. Beer, R. G. Hill &
schizophrenia: M. Campbell, P. I. Young, D. N. Bateman, J. Longmore
J. M. Smith & S. H. L. Thomas The effects of age on human venous responsiveness to
The therapeutic monitoring of antimicrobial agents: neuropeptide Y: M. L. Lambert, I. D. Callow, Q. P. Feng
E. J. Begg, M. L. Barclay & C. J. M. Kirkpatrick & J. M. O. Arnold
Role of nitric oxide in isoprenaline and sodium
nitroprusside-induced relaxation in human hand veins:
Drug metabolism and disposition S. Chalon, B. Tejura, H. Moreno Jnr, A. Urae,
T. F. Blaschke & B. B. Hoffman
Comparison of urinary 6B-hydroxycortisol/cortisol ratio
between neonates and their mothers: H. Nakamura,
Pharmacovigilance
A. Hasegawa, M. Kimura, S.-I. Yamagata, H. Nakasa,
A comparison of the use, effectiveness and safety of
H. Osada, S. Sekiya, S. Ohmori & M. Kitada bezafibrate, gemfibrozil and simvastatin in normal
Binding of propofol to blood components: implications
practice using the New Zealand Intensive Medicines
for pharmacokinetics and for pharmacodynamics:
Monitoring Programme (IMMP): P. W. Beggs,
J. X. Mazoit & K. Samii
D. W. J. Clark, S. M. Williams & D. M. Coulter
Record-linkage for pharmacovigilance in Scotland:
J. M. M. Evans & T. M. MacDonald
Pharmacokinetics Cough and angiotensin II receptor antagonists: cause or
Pharmacokinetics of flutamide in patients with renal confounding?: F. J. Mackay, G. L. Pearce & R. D. Mann
insufficiency: S. Anjum, S. K. Swan, L. J. Lambrecht,
E. Radwanski, D. L. Cutler, M. B. Affrime & Short reports
C. E. Halstenson Reliability of the omeprazole hydroxylation index for
A study of the relative bioavailability of cysteamine CYP2C19 phenotyping: possible effect of age, liver
hydrochloride, cysteamine bitartrate and disease and length of therapy: M. Kimura, I. Ieiri,
phosphocysteamine in healthy adult male volunteers: Y. Wada, K. Mamiya, A. Urae, E. limori, T. Sakai,
L. Tennezé, V. Daurat, A. Tibi, P. Chaumet-Riffaud & K. Otsubo & S. Higuchi
C. Funck- Brentano CYP2D6 polymorphism in a Gabonese population:
The pharmacokinetic modelling of G1198745 contribution of the CYP2D6*2 and CYP2D6*17 alleles
(dutasteride), a compound with parallel linear and to the high prevalence of the intermediate metabolic
nonlinear elimination: P. O. Gisleskog, D. Hermann, phenotype: S. Panserat, L. Sica, N. Gérard, H. Mathieu,
M. Hammarlund-Udenaes & M. O. Karlsson E. Jacqz-Aigrain & R. Krishnamoorthy
Volume 47, Number 2, February 1999
Reviews Drug metabolism and disposition
Regression of left ventricular hypertrophy; what are Tolterodine does not affect the human in vivo metabolism of
appropriate therapeutic objectives?: D. J. Sheridan, the probe drugs caffeine, debrisoquine and omeprazole:
M. P. Kingsbury & N. A. Flores N. Brynne, Y. Béttiger, B. Hallén & L. Bertilsson
Therapeutic drug monitoring of antimetabolic cytotoxic Pharmacokinetics of tolbutamide in ethnic Chinese:
drugs: L. Lennard A. S. Gross, S. Bridge & G. M. Shenfield
Adrenoceptors Incidence and risk factors for hyponatraemia following
Evaluation of the effect on heart rate variability of a treatment with fluoxetine or paroxetine in elderly people:
f.-adrenoceptor agonist and antagonist using non-linear T. J. Wilkinson, E. J. Begg, A. C. Winter & R. Sainsbury
scatterplot and sequence methods: C. G. Hanratty, B. Silke The effect of steady-state ropinirole on plasma
& J. G. Riddell concentrations of digoxin in patients with Parkinson’s
Platelet %,-adrenoceptor alterations in patients with disease: A. Taylor, A. Beerahee, D. Citerone, M. Davy,
essential hypertension: K. Varani, S. Gessi, A. Caiazza, K. Fitzpatrick, A. Lopez-Gil & F. Stocchi
G. Rastelli, F. Portaluppi & P. A. Borea
Contribution of nitric oxide to B,-adrenoceptor mediated
vasodilatation in human forearm arterial vasculature:
N. G. Majmudar, D. Anumba, S. C. Robson & G. A. Ford
Letters to Editors
Pharmacodynamics Effects of ketoconazole on the erythromycin breath test
Fosinopril reduces left ventricular mass in untreated and the dapsone recovery ratio: M. T. Kinirons,
hypertensive patients: a controlled trial: B. M. Y. Cheung & Y. Krivoruk, G. R. Wilkinson & A.J . J. Wood
C.-P. Lau Potentiation of acenocoumarol during vaginal
The haemodynamic effect of the 5HT, agonist administration of miconazole: D. Lansdorp,
BMS-180048: a class effect of triptans?: L. Swan, S. Hood, H. P. H. M. Bressers,J . A. M. Dekens-Konter &
D. H. Bimie, D. F. Muir, G. P. McCann & WS. Hillis R. H. B. Meyboom
The effects of vapreotide, a somatostatin analogue, on Visual hallucinations due to radiocontrast media. Report
gastric acidity, gallbladder emptying and hormone release of two cases and review of the literature: A. Iliopoulou,
after 1 week of continuous subcutaneous infusion in G. Giannakopoulos, P. Goutou, H. Pagou &
normal subjects: M. A. Ritz,J . Drewe, A. Ziel, S. Stamatelopoulos
P. Hildebrand, P. Schneider, N. Lahlou & C. Beglinger Adverse effects of herbal remedies and OTC medicines:
D. Shaw, V. Murray & G. Volans
Adverse reactions Providing patients with written information helps them to
Glomerular, tubular and interstitial nephritis associated with be aware of and report adverse drug reactions?: K. Harada,
non-steroidal antiinflammatory drugs. Evidence of a S. Yamazaki & A. Fujimura
common mechanism: U. Ravnskov A reply:J . Barnes & S. Mills
Volume 47, Number 3, March 1999
Reviews Pharmacokinetics of glycosylated recombinant human
Clinical pharmacy—a hospital perspective: R. T. Calvert granulocyte colony-stimulating factor (lenograstim) in
Clinical case studies in heart failure management: healthy male volunteers: A. C. Houston, L. A. Stevens &
R. J]. MacFadyen, P. Shiels & A. D. Struthers V. Cour
Pharmacokinetic profile of alniditan nasal spray during
Pharmacokinetics and outside migraine attacks: K. I. Roon, P. A. Soons,
Dose linearity study of selegiline pharmacokinetics after M. P. Uitendaal, F. de Beukelaar & M. D. Ferrari
oral administration: evidence for strong drug interaction
with female sex steroids: K. Laine, M. Anttila, Drug metabolism and disposition
A. Helminen, H. Karnani & R. Huupponen Metabolic interactions between mibefradil and HMG-
The pharmacokinetics and safety profile of oral CoA reductase inhibitors: an in vitro investigation with
ganciclovir in combination with trimethoprim in human liver preparations: T. Prueksaritanont, B. Ma,
HIV- and CMV-seropositive patients: D. Jung, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider,
M. H. AbdelHameed,J . Hunter, P. Teitelbaum, A. Dorr & J. H. Lin & T. A. Baillie
K. Griffy Cytochrome P450 isoform selectivity in human hepatic
Pharmacokinetics of intravenous and oral L-arginine in theobromine metabolism: S. Gates & J. O. Miners
normal volunteers: O. Tangphao, M. Grossmann,
S. Chalon, B. B. Hoffman & T. F. Blaschke Pharmacodynamics
Interpretation of middle ear fluid concentrations of Risk of ventricular arrhythmias associated with
antibiotics: comparison between ceftibuten, cefixime and nonsedating antihistamine drugs: F. J. de Abajo &
azitromycin: F. Scaglione, G. Demartini, S. Dugnani, L. A. G. Rodriguez
M. M. ArcidiaconoJ, . P. Pintucci & F. Fraschini Combined oestrogen—progestogen replacement therapy
The absorption profile and availability of a physiological does not inhibit low-density lipoprotein oxidation in
subcutaneously administered dose of recombinant human postmenopausal women: Y. Wen, M. C. T. Doyle,
growth hormone (GH) in adults with GH deficiency: L. A. Norris, M. M. Sinnott, T. Cooke, R. F. Harrison &
Y. J. H. Janssen, M. Frélich & F. Roelfsema J. Feely
Therapeutics Effect of electrostatic charge in plastic spacers of the
Low use of long-term hormone replacement therapy in lung delivery of HFA-salbutamol in children: J. Anhoj,
Denmark: C. Olesen, F. H. Steffensen, H. T. Sorensen, H. Bisgaard & B. J. Lipworth
G. L. Nielsen,J . Olsen & U. Bergman
Short reports Letter to Editor
Is reporting rate a good predictor of risks associated with Angiotensin II receptor subtype I antagonism and
drugs?: C. Pierfitte, B. Bégaud, R. Lagnaoui & diastolic cardiac filling in man: P. Shiels, P. O. Lim,
N. D. Moore A. C. Leary, A. D. McMahon & T. M. MacDonald
Volume 47, Number 4, April 1999
Review Methadone N-demethylation in human liver
Therapeutic drug monitoring of immunosuppressant microsomes: lack of stereoselectivity and involvement of
drugs: A. Johnston & D. W. Holt CYP3A4: D. J. R. Foster, A. A. Somogyi & F. Bochner
Drug delivery
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and bioavailability of oral 5’-deoxy-
Chronopharmacology of intravenous and oral modified
5-fluorouridine in cancer patients: S. A. M. Van Der
release verapamil: K. Dilger, K. Eckhardt, U. Hofmann,
Heyden, M. S. Highley, E. A. De Bruijn, U. R. Tjaden,
K. Kucher, G. Mikus & M. Eichelbaum
H. J. E. M. Reeuwijk, H. Van Slooten, A. T. Van
Oosterom & R. A. A. Maes
A comparative analysis of the particle size output of Pharmacodynamics
beclomethasone diproprionate, salmeterol xinafoate and Midazolam effects on prepulse inhibition of the acoustic
fluticasone propionate metered dose inhalers used with blink reflex: H. Schachinger, B. U. Miiller, W. Strobel,
the babyhaler, volumatic and aerochamber spacer W. Langewitz & R. Ritz
devices: P. W. Barry & C. O'Callaghan Impaired B-adrenoceptor mediated venodilation in
patients with diabetes mellitus: K. Harada, M. Ohmori,
Pharmacokinetics Y. Kitoh, K.-I. Sugimoto & A. Fujimura
Estimation of the initial distribution volume of glucose Effect of troglitazone on plasma lipid metabolism and
by an incremental plasma glucose level at 3 min after i.v. lipoprotein lipase:J . Kobayashi, I. Nagashima, M. Hikita,
glucose in humans: K. Hirota, H. Ishihara, T. Tsubo & H. Bujo, K. Takahashi, M. Otabe, N. Morisaki & Y. Saito
A. Matsuki
A pharmacokinetic model for alpha interferon Drug interaction
administered subcutaneously: E. Chatelut, L. Rostaing, A placebo-controlled study of interaction between
N. Grégoire, J.-L. Payen, A. Pujol,J . lzopet, G. Houin & nabumetone and acenocoumarol: A. Pardo,
P. Canal M. Garcia-Losa, A. Fernandez-Pavon, S. del Castillo,
Pharmacokinetics and tolerability of oral rizatriptan
T. Pascual-Garcia, E. Garcia-Méndez & R. Dal-Ré
in healthy male and female volunteers: Y. Lee,
J. A. Conroy, M. E. Stepanavage, C. M. Mendel,
Short reports
G. Somers, D. A. McLoughlin, T. V. Olah, M. De Smet,
Functional significance of a CA polymorphism in
B. Keymeulen & J. D. Rogers
intron 1 of the cytochrome P450 CYP1A2 gene tested
Pharmacokinetic variability and strategy for therapeutic
with caffeine: C. Sachse,J . Brockméller, S. Bauer &
drug monitoring of saquinavir (SQV) in HIV-1 infected
I. Roots
individuals: M. B. Regazzi, P. Villani, R. Maserati,
Effect of the CYP2D6*10 genotype on venlafaxine
L. Cocchi, R. Giacchino, D. Burroni & M. Rettani
pharmacokinetics in healthy adult volunteers:
T. Fukuda, I. Yamamoto, Y. Nishida, Q. Zhou,
Drug disposition
M. Ohno, K. Takada & J. Azuma
Cellular uptake of fluvastatin, an inhibitor of HMG-CoA
Ticlopidine decreases the in vivo activity of CYP2C19 as
reductase, by rat cultured hepatocytes and human aortic
measured by omeprazole metabolism: T. Tateishi,
endothelial cells: M. Ohtawa, N. Masuda, I. Akasaka,
T. Kumai, M. Watanabe, H. Nakura, M. Tanaka &
A. Nakashima, K. Ochiai & M. Moriyasu
S. Kobayashi
Pain-mediated altered absorption and metabolism of
ibuprofen: an explanation for decreased serum
enantiomer concentration after dental surgery: F. Jamali Letters to the Editors
& C. M. Kunz-Dober (S)-ketoprofen accumulation in premature neonates with
Dietary caffeine as a probe agent for assessment of renal failure who were exposed to the racemate during
cytochrome P4501A2 activity in random urine samples: pregnancy: B. Bannwarth, F. Lagrange, F. Péhourcq,
A. Nordmark, S. Lundgren, S. Cnattingius & A. Rane B. Llanas & J. L. Demarquez
Serum concentrations and clinical effects of risperidone 463P Proceedings of the Dutch Society for Clinical
in schizophrenic patients in Singapore—a preliminary Pharmacology and Biopharmacy Meeting,
report: H. S. Lee, C. H. Tan, Y. M. Khoo, K. T. Chee, 2 October 1998
K. E. Wong, S. A. Chong, R. Mahendran, H. L. Yap,
B. L. Low, C. H. Choo & A. Chan
Volume 47, Number 5, May 1999
Review Pharmacokinetic-pharmacodynamic profile of systemic
Why does spironolactone improve mortality over and nitric oxide-synthase inhibition with t-NMMA in
above an ACE inhibitor in chronic heart failure?: humans: B. X. Mayer, C. Mensik, S. Krishnaswami,
A. D. Struthers H. Derendorf, H.-G. Eichler, L. Schmetterer & M. Wolzt
Pharmacokinetics
Integrated modelling of the clinical pharmacokinetics of Drug disposition
SDZ HTF 919, a novel selective 5-HT, receptor Cytochrome P450 isoforms involved in metabolism
agonist, following oral and intravenous administration: of the enantiomers of verapamil and norverapamil:
S. Appel-Dingemanse, M.-O. Lemarechal, A. Kumle, T. S. Tracy, K. R. Korzekwa, F. J. Gonzalez &
M. Hubert & E. Legangneux I. W. Wainer
The influence of CYP2D6 activity on the kinetics of
propafenone enantiomers in Chinese subjects:
Pharmacodynamics W. M. Cai, B. Chen, M. H. Cai, Y. Chen &
Combination of calcium channel blockers and Y. D. Zhang
B-adrenoceptor blockers for patients with exercise-
induced angina pectoris: a double-blind parallel-group
comparison of different classes of calcium channel
Adverse drug reactions
blockers:J . A. F. M. van der Vring, M. C. G. Daniéls,
Retrospective analysis of the frequency and recognition
N. J. H. Holwerda, P. J. A. M. Withagen, A. Schelling,
of adverse drug reactions by means of automatically
T. J. Cleophas & M. G. C Hendriks
recorded laboratory signals: I. Tegeder, M. Levy,
Nisoldipine improves the impaired erythrocyte
U. Muth-Selbach, R. Oelkers, F. Neumann, H. Dormann,
deformability correlating with elevated intracellular free
T. Azaz-Livshits, M. Criegee-Rieck, H. T. Schneider,
calcium-ion concentration and poor glycaemic control in
E.-G. Hahn, K. Brune & G. Geisslinger
NIDDM:J . Fujita, K. Tsuda, T. Takeda, L. Yu,
S. Fujimoto, M. Kajikawa, M. Nishimura, N. Mizuno,
Y. Hamamoto, E. Mukai, T. Adachi & Y. Seino
Impaired cholinergic dilator response of resistance Pharmacovigilance
arteries isolated from patients with Raynaud’s disease: Use of dexfenfluramine, fenfluramine and phentermine
P. J. W. Smith, C. J. Ferro, D. S. McQueen & D. J. Webb and the risk of stroke: L. E. Derby, M. W. Myers &
H. Jick
Study of cardiac repolarization in healthy volunteers
performed with mizolastine, a new H,-receptor
antagonist: S. Chaufour, H. Caplain, C. L’Heéritier,
N. Lilienthal, C. Deschamps, C. Dubruc & P. Rosenzweig Letter to the Editors
Drug reactions to cotrimoxazole in HIV infection:
possibly not due to the hydroxylamine metabolites
Pharmacokinetics/pharmacodynamics
of sulphamethoxazole: H. J. M. ter Hofstede,
Pharmacokinetics and pharmacodynamics of Ro
A.J . A. M. van der Ven & P. P. Koopmans
44-3888 after single ascending oral doses of sibrafiban,
Transplacental distribution of labetalol stereoisomers at
an oral platelet aggregation inhibitor, in healthy male
volunteers: B. Wittke, I. J. Mackie, S.J. Machin, delivery: D. W. Boulton,J . M. Dakers,J . P. Fawcett &
T. M. Fiddes
U. Timm, M. Zell & T. Goggin
Clinical and pharmacokinetic results with a new
ultrashort-acting calcium antagonist, clevidipine,
following gradually increasing intravenous doses Proceedings
to healthy volunteers: H. Ericsson, C. Fakt, Proceedings of the British Pharmacological Society,
A. Jolin-Mellgard, M. Nordlander, L. Sohtell, Brighton, 6—8 January 1999
M. Sunzel & C. G. Regardh Erratum
Volume 47, Number 6, June 1999 Therapeutics of postoperative pain
Management of postoperative pain in abdominal surgery
in Spain. A muticentre drug utilization study:
Review A. Vallano, C. Aguilera,J . M. Amau, J.-E. Batios &
The management of Pneumocystis carinii pneumonia: J.-R. Laporte
F. J. Vilar, S. H. Khoo The efficacy of a novel adenosine agonist (WAG 994)
in postoperative dental pain: R. A. Seymour,
Commentary J. E. Hawkesford, C. M. Hill, J. Frame & C. Andrews
The interface between Clinical and Laboratory
Bioavailability Pharmacovigilance
A prospective study of adverse drug reactions in
Relative bioavailability of sodium cromoglycate to the
hospitalized children: I. Martinez-Mir, M. Garcta-Lopez,
lung following inhalation, using urinary excretion:
V. Palop,J . M. Ferrer, E. Rubio & F. J. Morales-Olivas
O. A. Aswania, S. A. Corlett & H. Chrystyn
Systemic availability of budesonide after nasal Signalling possible drug—drug interactions in a
spontaneous reporting system: delay of withdrawal
administration of three different formulations:
pressurized aerosol, aqueous pump spray, and powder: bleeding during concomitant use of oral contraceptives
L. Thorsson, O. Borga & S. Edsbacker and itraconazole: E. P. van Puijenbroek, A. C. G. Egberts,
R. H. B. Meyboom & H. G. M. Leufkens
Drug disposition
Microsomal prediction of in vivo clearance of CYP2C9
Clinical pharmacy
substrates in humans: D.J . Carlile, N. Hakooz, Clinical pharmacy interventions by community
M. K. Bayliss & J. B. Houston pharmacists during the dispensing process:
G. M. Hawksworth, A.J . Corlett, D. J. Wright
Population pharmacokinetics & H. Chrystyn
Pharmacokinetics of gentamicin in 957 patients with
varying renal function dosed once daily:
C. M. J. Kirkpatrick, S. B. Duffull & E. J. Begg Short report
The effect of bosentan on the pharmacokinetics of
Pharmacokinetics and pharmacodynamics digoxin in healthy male subjects: C. Weber, L. Banken,
Pharmacokinetics and haemodynamics of candesartan H. Birnboeck, S. Nave & R. Schulz
cilexetil in hypertensive patients on regular
haemodialysis: M. Pfister, F. Schaedeli, F. J. Frey &
Letter to the Editors
D. E. Uehlinger
Loss of blood pressure control on withdrawal of
Pharmacokinetics, induction of anaesthesia and safety
fluconazole during nifedipine therapy: B. Kremens,
characteristics of Propofol 6% SAZN vs Propofol 1%
E. Brendel, M. Bald, P. Czyborra & M. C. Michel
SAZN and Diprivan®-10 after bolus injection:
C. A.J . Knibbe, H.-J. Voortman, L. P. H. J. Aarts,
P. F. M. Kuks, R. Lange, H. J. M. Langemeijer & Book reviews
M. Danhof Self-assembling delivery complexes for gene delivery:
from laboratory to clinical trialJ: . Steiner
Vascular pharmacodynamics What should a clinical pharmacologist know to start a
Ursodeoxycholic acid and endothelial-dependent, nitric
clinical trial (phase I and II)?: P. R. Jackson
oxide-independent vasodilatation of forearm resistance
Improving the regulatory review process: P. Waller
arteries in patients with coronary heart disease:
J. Sinisalo, H. Vanhanen, P. Pajunen, H. Vapaatalo &
M. S. Nieminen Indexes to Volume 47